A biopharmaceutical company engaged in developing treatments for rare diseases, with a focus on schizophrenia, and has 18 FDA-approved drugs in its portfolio.
0
Orphan Designations
18
FDA Approvals
Latest: XARELTO (2021)
0
Active Trials
2
Rare Diseases
across 2 areas
0
News (30d)
Quiet
Janssen Pharmaceuticals, Inc. is a company with 0 orphan drug designations across 2 rare diseases, including 18 FDA-approved therapies. 2 active policy bills affect their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| schizophrenia | RISPERDAL CONSTA | Des.TrialAppr. |
| schizophrenia 1 | RISPERDAL CONSTA | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
2
affecting portfolio
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
2
affecting portfolio